Financial & competing interests disclosure
Michail Vikelis has consulted for, advised or spoken for AstraZeneca Greece, Janssen-Cilag Greece and Novis Pharmaceuticals Greece. Alan M Rapoport has consulted or spoken for Abbott India, Allergan, Endo, Forest, Janssen India, MAP Pharmaceuticals, Merck, Nautilus Neurosciences, NuPathe, Pfizer and Zogenix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.